About this item:

291 Views | 499 Downloads

Author Notes:

Address for correspondence: Scott K. Fridkin, Division of Healthcare Quality Promotion, Mailstop A35, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, USA; fax: 404-639-6458; e-mail: skf0@cdc.gov

We thank the infection-control and microbiology personnel from the participating Intensive Care Antimicrobial Resistance Epidemiology (ICARE) Project hospitals for reporting the data for this study.

Subjects:

Research Funding:

This work was supported in part by grants to the Rollins School of Public Health of Emory University for Phases 2 and 3 of Project ICARE by AstraZeneca Pharmaceuticals (Wilmington, DE), Pfizer, Inc. (New York, NY), and Roche Laboratories (Nutley, NJ) as full sponsors, and Aventis Pharma (formerly Rhone-Poulenc Rorer) (Collegeville, PA), the National Foundation for Infectious Diseases (Bethesda, MD), the American Society for Health Systems Pharmacists Research and Education Foundation (Bethesda, MD), Kimberly-Clark Corporation (Roswell, GA), and Bayer Corporation, Pharmaceuticals Division (West Haven, CT) as partial sponsors.

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Immunology
  • Infectious Diseases
  • UNITED-STATES
  • STAPHYLOCOCCUS-AUREUS
  • NOSOCOMIAL INFECTIONS
  • KLEBSIELLA-PNEUMONIAE
  • SURVEILLANCE PROGRAM
  • SUSCEPTIBILITY
  • PATHOGENS
  • PATTERNS
  • SYSTEM
  • RATES
  • Antibiotic resistance
  • Nosocomial infections
  • Surveillance
  • Epidemiologic Methods

Temporal changes in prevalence of antimicrobial resistance in 23 US hospitals

Tools:

Journal Title:

Emerging Infectious Disease

Volume:

Volume 8, Number 7

Publisher:

, Pages 697-701

Type of Work:

Article | Final Publisher PDF

Abstract:

Antimicrobial resistance is increasing in nearly all health-care-associated pathogens. We examined changes in resistance prevalence during 1996-1999 in 23 hospitals by using two statistical methods. When the traditional chi-square test of pooled mean resistance prevalence was used, most organisms appear to have increased in prevalence. However, when a more conservative test that accounts for changes within individual hospitals was used, significant increases in prevalence of resistance were consistently observed only for oxacillin-resistant Staphylococcus aureus, ciprofloxacin-resistant Pseudomonas aeruginosa, and ciprofloxacin- or ofloxacin-resistant Escherichia coli. These increases were significant only in isolates from patients outside intensive-care units (ICU). The increases seen are of concern; differences in factors present outside ICUs, such as excessive quinolone use or inadequate infection-control practices, may explain the observed trends.

Copyright information:

Articles from Emerging Infectious Diseases are provided here courtesy of Centers for Disease Control and Prevention

Export to EndNote